All sponsors

Alnylam Pharmaceuticals $ALNY

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS13
PHASE 3 / 2-35
RECRUITING7
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO25%

Delay Index: of 8 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Alnylam Pharmaceuticals on the live radar map → 📅 $ALNY readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Vutrisiran
NCT04153149
P3Active, not recruitingTransthyretin Amyloidosis (ATTR) With Cardiomyopathy6552024-05-08
ALN-2232
NCT07463846
P1/2RecruitingObesity1562027-04-28
ALN-4324
NCT07465224
P2Active, not recruitingType 2 Diabetes Mellitus (T2DM)242027-05-28
HMBeacon
NCT07575308
P2RecruitingVon Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB)242027-06-30
cAPPricorn-1
NCT06393712
P2Active, not recruitingCerebral Amyloid Angiopathy2102027-08-09 (+1 mo)
ALN-4324
NCT06845202
P1/2Active, not recruitingObese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM)1052027-08-31 (+14 mo)
TRITON-PN
NCT07223203
P3RecruitingHereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN1252027-12-27
InsigHHT
NCT06659640
P1/2Active, not recruitingHereditary Hemorrhagic Telangiectasia892028-01-05 (+19 mo)
Vutrisiran
NCT06679946
P3Enrolling by invitationTransthyretin Amyloidosis (ATTR) With Cardiomyopathy7002028-03-31 (-3 mo)
ALN-AGT01 RVR
NCT07553442
P2RecruitingHypertension932028-04-01
Mivelsiran
NCT07636811
P2RecruitingDown Syndrome-Associated Alzheimer's Disease (DS-AD)582030-05-18
Nucresiran
NCT07052903
P3RecruitingTransthyretin Amyloidosis With Cardiomyopathy22502030-05-28
ZENITH
NCT07181109
P3RecruitingHigh Risk Cardiovascular Disease; Hypertension110002030-09-23 (-1 mo)